European thyroid journal · 2026
Iopanoic acid rapidly restores euthyroidism in refractory thyrotoxicosis pre-thyroidectomy: a retrospective study.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Newman Christine, Saqlain Muhammed, Mohammed Isra Ahmed, Bell Daniel, Lyons Greta, Jani Piyush, Fish Brian, Wood Diana, Tapa Denise, Halsall David, Oddy Susan, Chatterjee Krishna, Schoenmakers Nadia, Moran Carla
Аннотация
OBJECTIVE: Restoration of euthyroidism in patients with thyrotoxicosis prior to thyroidectomy is recommended to decrease perioperative morbidity and thyroid storm risk. This is challenging when conventional anti-thyroid medication is contraindicated or ineffective. Iopanoic acid (IOPA), an iodinated contrast medium formerly used as an oral cholecystographic agent, may facilitate treatment of thyrotoxicosis, but limited manufacture precludes its use in the UK. We investigated the effectiveness and safety of IOPA for optimizing thyroid status in treatment-resistant thyrotoxicosis prior to thyroidectomy at a referral centre.
METHODS: With prior permission of our Drug and Therapeutics Committee, we sourced laboratory-grade (>98% pure) IOPA and administered this orally to control ongoing, severe thyrotoxicosis prior to thyroidectomy in 12 patients with inadequate response to standard therapies. Underlying aetiologies included Graves' disease, amiodarone-induced thyrotoxicosis, toxic multinodular goitre and resistance to thyroid hormone beta. Medical case notes were reviewed retrospectively to analyse clinical and biochemical outcomes.
RESULTS: All patients exhibited a decline and normalization/near-normalization of free T3 (FT3) levels (mean 55% decrease, SEM 4.5%), with minimal changes in FT4 levels. Eleven patients proceeded to uneventful thyroidectomy, and IOPA was well tolerated with no directly attributable side effects.
CONCLUSION: IOPA is a safe and effective agent for controlling biochemical thyrotoxicosis in preparation for thyroidectomy, including disease refractory to conventional medication. Highly pure, laboratory-grade iopanoic acid that is approved for human use is now available in the UK; consideration should be given to more widespread use for emergency treatment of life-threatening hyperthyroidism.
METHODS: With prior permission of our Drug and Therapeutics Committee, we sourced laboratory-grade (>98% pure) IOPA and administered this orally to control ongoing, severe thyrotoxicosis prior to thyroidectomy in 12 patients with inadequate response to standard therapies. Underlying aetiologies included Graves' disease, amiodarone-induced thyrotoxicosis, toxic multinodular goitre and resistance to thyroid hormone beta. Medical case notes were reviewed retrospectively to analyse clinical and biochemical outcomes.
RESULTS: All patients exhibited a decline and normalization/near-normalization of free T3 (FT3) levels (mean 55% decrease, SEM 4.5%), with minimal changes in FT4 levels. Eleven patients proceeded to uneventful thyroidectomy, and IOPA was well tolerated with no directly attributable side effects.
CONCLUSION: IOPA is a safe and effective agent for controlling biochemical thyrotoxicosis in preparation for thyroidectomy, including disease refractory to conventional medication. Highly pure, laboratory-grade iopanoic acid that is approved for human use is now available in the UK; consideration should be given to more widespread use for emergency treatment of life-threatening hyperthyroidism.